ReviewFrontiers in chemistry2025
Advances in electrochemical biosensors for the detection of tumor-derived exosomes.
Review in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Electrochemical Biosensors for Circulating Tumor Cells and ctDNA: Emerging Strategies for Precision Oncology.Annals of biomedical engineering · 2026Review
- Electrochemical Biosensors for Exosome Detection: Current Advances, Challenges, and Prospects for Glaucoma Diagnosis.Sensors (Basel, Switzerland) · 2026Review
- Extracellular RNAs as Messengers and Early Biomarkers in Neurodegeneration.International journal of molecular sciences · 2025Review
- Advances in Colorectal Cancer: Epidemiology, Gender and Sex Differences in Biomarkers and Their Perspectives for Novel Biosensing Detection Methods.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Exosomal biomarkers in leukemia: translational potential and regulatory challenges for precision medicine applications.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes, released from diverse cells as nanoscale lipid bilayer vesicles, mediate intercellular communication and participate in various physiological and pathological processes. Thereinto, tumor-derived exosomes (T-EXOs) with molecular cargoes of parent tumor cells act as attractive biomarkers for tumor liquid biopsy. The amount of T-EXOs and their levels of contained specific proteins and nucleic acids are closely associated with cancer burden and classification. Nevertheless, the nanoscale size and relatively low abundance of exosomes, as well as complex body liquid matrix pose daunting challenges for efficient isolation and sensitive detection of T-EXOs. Biosensing as fast, convenient and accurate method, has been widely employed for the detection of biomarkers over the past decades. Among them, electrochemical sensors can sensitively detect biomarkers by measuring of the change of electrical signal caused by oxidation or reduction at the working electrode surface. This review aims to summarize the recent advance in electrochemical biosensors for quantification, and protein and RNA analysis of exosomes. Further, challenges and future perspectives for exosome-based liquid biopsy have been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.